Welcome to our dedicated page for Wuxi Biologics news (Ticker: WXXWY), a resource for investors and traders seeking the latest updates and insights on Wuxi Biologics stock.
WuXi Biologics (WXXWY) provides comprehensive biologics development solutions through its global CRDMO platform. This news hub delivers essential updates for stakeholders tracking the company's operational milestones and industry impact.
Access timely reports on regulatory achievements, technology innovations, and strategic partnerships. Our curated collection includes earnings announcements, manufacturing capacity expansions, and GMP certification milestones across global facilities. Monitor developments in proprietary platforms like WuXiBody™ bispecific antibodies and WuXia™ cell line technologies.
This resource consolidates verified information from multiple sources, offering efficient tracking of the company's progress in biologics development. Regular updates ensure you stay informed about critical events affecting WXXWY's market position and service capabilities.
Bookmark this page for streamlined access to WuXi Biologics' latest developments. Combine these updates with financial filings and industry analysis for complete due diligence.
WuXi Biologics, a global leader in Contract Research, Development and Manufacturing, announced its subsidiary WuXi Biologics (Shanghai) Co., Ltd. was removed from the U.S. Department of Commerce's Unverified List (UVL), effective Dec. 16, 2022. This follows successful on-site checks by the Department in cooperation with China's Ministry of Commerce. Both subsidiaries faced UVL placement in February 2022 due to verification delays for U.S. exports, but since then, compliance has been reaffirmed. WuXi Biologics remains committed to high compliance standards and advancing its Environmental, Social, and Governance (ESG) initiatives.
WuXi Biologics has reported significant progress amid industry challenges, with 120 new projects signed in 2022 and similar goals for 2023. The company is reaffirming its growth targets for the year. A notable achievement includes a successful share repurchase of approximately US$300 million, acquiring over 50 million shares at HK$45.90 each. Additionally, its subsidiary was removed from the U.S. Department of Commerce's Unverified List after a successful site visit, enhancing compliance credibility. WuXi Biologics continues to position itself as a leader in ESG initiatives within its sector.
WuXi Biologics has launched its 11th GMP drug substance manufacturing facility, MFG8, in Shijiazhuang, Hebei Province, China. This new facility enhances production capabilities, allowing for commercial manufacturing at scales from 4,000L to 20,000L and project initiation within four weeks. MFG8 incorporates eco-friendly practices in line with WuXi's ESG commitments, featuring sustainable construction and a rooftop solar project to significantly reduce carbon emissions. The facility supports the growing global demand for contract biomanufacturing services and aims to provide reliable, flexible services in biologics manufacturing.
WuXi Biologics has announced the completion of its new drug product facility DP8 in Hangzhou, China, which has successfully manufactured its first GMP batch. This facility is the tenth in WuXi's global network and features advanced technologies including SA25 robotic filling and mRNA-LNP encapsulation. The DP8 facility enhances WuXi's ability to provide end-to-end integrated solutions for diverse drug modalities. WuXi supports 534 integrated projects, signaling robust growth in its operations.
WuXi XDC, a global CRDMO leader, received the Runner Up prize for 'Best Contract Manufacturing Provider' at the 2022 World ADC Awards. This recognition highlights WuXi XDC's commitment to advancing antibody-drug conjugates (ADCs) and its integrated services. Over 700 industry votes determined the nominees, showcasing the company’s significant reputation in the sector. CEO Dr. Jimmy Li emphasized the importance of this award as a testament to their advanced technology and expedited development timelines, achieving an industry-leading DNA-to-IND timeline of 15 months.
WuXi Biologics, a global leader in biologics manufacturing, has been awarded the "Best CDMO Award of the Year" at the Asia-Pacific Biologics CMO Excellence Awards 2022, signifying its excellence in cost-effective and high-quality biologics production. This accolade reflects the trust of over 200 voting biopharma companies. The company supports 534 integrated client projects and emphasizes its commitment to sustainability through an active Environmental, Social, and Governance (ESG) strategy.
WuXi Biologics and Toregem BioPharma announced a strategic partnership to develop TRG035, a monoclonal antibody targeting USAG-1 for congenital adentia. This collaboration will leverage WuXi Biologics' comprehensive CMC services, including GMP manufacturing and bioassay development, to support Toregem's Investigational New Drug (IND) application. The Phase I clinical trial for TRG035 is slated to commence in early 2024. WuXi Biologics aims to enhance its global footprint while focusing on innovative biologics solutions for patients.
WuXi Biologics, a global leader in Contract Research, Development and Manufacturing, announced that its subsidiary, WuXi Biologics Co., Ltd., was removed from the U.S. Department of Commerce's Unverified List (UVL) as of October 7, 2022. This follows a successful on-site end-use check completed in June 2022. The company aims to maintain high compliance standards and is working towards delisting its other subsidiary, WuXi Biologics (Shanghai) Co., Ltd. WuXi Biologics is committed to sustainability and enhancing its ESG strategy.
WuXi Biologics held a topping-off ceremony for its new commercial biomanufacturing facility in Worcester, Massachusetts, on September 28, 2022. The 189,500 sq. ft. facility, set to complete in 2024, aims to create 250 jobs and enhance the local biotech ecosystem. Speakers at the event included Massachusetts Lieutenant Governor Karyn Polito and CEO Dr. Chris Chen, emphasizing the facility's role in strengthening the supply chain for biologics. WuXi Biologics supports 534 client projects globally, with a commitment to sustainable practices.
WuXi Biologics announced regulatory approvals for its Drug Substance (DS) facilities and Drug Product (DP) facility in Wuxi, China, from the European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA). The MFG5 facility, with a capacity of 60,000L, and the DP2 facility received EMA GMP certificates within 10 months of starting GMP manufacturing. WuXi Biologics now holds 13 certified DS and DP facilities globally, expanding its capacity to support clients with commercial manufacturing. CEO Chris Chen emphasized the commitment to maintaining high global quality standards.
